163 results on '"Nakada, Marian T."'
Search Results
2. Supplementary Figure 1 from Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix Metalloproteinases
3. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis
4. Interplay between inflammation and tumor angiogenesis
5. Tumor Necrosis Factor and Cancer
6. Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist
7. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies
8. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells
9. c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model
10. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke: A preliminary feasibility and safety study in a non-human primate model
11. Abciximab Pharmacodynamics Are Unaffected by Antecedent Therapy with Other GPIIb/IIIa Antagonists in Non-Human Primates
12. Platelets inhibit the lysis of pulmonary microemboli
13. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM)
14. Clinical Success of Antibody Therapeutics in Oncology
15. Prognostic impact of extracellular matrix metalloprotease inducer: Immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer
16. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models
17. Clot Lysis in a Primate Model of Peripheral Arterial Occlusive Disease with Use of Systemic or Intraarterial Reteplase: Addition of Abciximab Results in Improved Vessel Reperfusion
18. Tumor necrosis factor-α in the pathogenesis and treatment of cancer
19. Pecam-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide
20. Glycoprotein IIb/IIIa Antagonist, Murine 7E3 F(ab`)2, and Tissue Plasminogen Activator in Focal Ischemia: Evaluation of Efficacy and Risk of Hemorrhage With Combination Therapy
21. Platelets and Cancer: Implications for Antiangiogenic Therapy
22. Regulation of PECAM-1 in Endothelial Cells during Cell Growth and Migration
23. The β3 Integrin Antagonist m7E3 Reduces Matrix Metalloproteinase Activity and Smooth Muscle Cell Migration
24. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro™)
25. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates
26. Loss of Endothelial Surface Expression of E-Selectin in a Patient With Recurrent Infections
27. Separate pathways for cellular uptake of ferric and ferrous iron
28. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells
29. αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
30. Alpha-v Integrins as Therapeutic Targets in Oncology
31. A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology
32. Regulation of Vascular Endothelial Growth Factor Expression by EMMPRIN via the PI3K-Akt Signaling Pathway
33. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy
34. Therapeutic Effect of Anti–TNF-α Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibody–Associated Systemic Vasculitis
35. Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix Metalloproteinases
36. A Novel Interleukin-IL-6 (IL-6) Dependent Syngeneic Multiple Myeloma (MM) Model in SCID Mice.
37. Interterleukin-6 (IL-6) Produced by Monocyte Activation Reduces Dendritic Cell (DC) Differentiation in Patients with Multiple Myeloma (MM) and Malignant Lymphoma (ML): Role of CNTO 328, an Anti-IL-6 Monoclonal Antibody (Mab) and Possible Clinical Applications.
38. Enhanced Tumor Inhibition of MDA-MB-231 Breast Carcinoma by the Anti-Tissue Factor Antibody, CNTO 860, Is Mediated by Antibody Dependent Cellular Cytotoxicity
39. Tumor-Stroma Interaction: Positive Feedback Regulation of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression and Matrix Metalloproteinase-Dependent Generation of Soluble EMMPRIN
40. CNTO 95, a fully human monoclonal antibody that inhibits ?v integrins, has antitumor and antiangiogenic activityin vivo
41. Tumor Necrosis Factor and Cancer.
42. Monoclonal antibodies as therapeutics in oncology
43. Effect of anti-tumor necrosis factor-α polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model
44. Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization
45. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats
46. Divergent Effects of Platelet-Endothelial Cell Adhesion Molecule-1 and β3 Integrin Blockade on Leukocyte Transmigration In Vivo
47. Contortrostatin, a Homodimeric Disintegrin, Binds to Integrin αvβ5
48. Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment
49. Effects of β3-Integrin Blockade (c7E3) on the Response to Angioplasty and Intra-Arterial Stenting in Atherosclerotic Nonhuman Primates
50. Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and α v β 3 Integrins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.